[Biomarkers for cancer immunotherapy].

Yutaka Kawakami, Yoshie Kawase, Azusa Ohizumi, Shinobu Noji, Toshiharu Sakurai, Tomonobu Fujita

Research output: Contribution to journalArticle

Abstract

Immune-biomarkers and -assays are important for development of cancer immunotherapy to select the patients who are expected to respond to immunotherapy before or early after immunotherapy, to monitor immune induction following immunotherapy, and to evaluate anti-tumor effects early after immunotherapy. Comprehensive immune-evaluation including positive and negative immune responses against cancer cells and identification of blood biomarkers which reflect immune-conditions in tumor microenvironment are required although direct evaluation of tumor tissues can be possible for some patients. Importance of immune responses has recently been recognized even for standard cancer treatments including chemotherapy and molecular target therapy. Therefore, immunological biomarkers may be useful for any cancer treatment.

Original languageEnglish
Pages (from-to)759-766
Number of pages8
JournalNihon rinsho. Japanese journal of clinical medicine
Volume70
Issue number5
Publication statusPublished - 2012 May

Fingerprint

Tumor Biomarkers
Immunotherapy
Neoplasms
Biomarkers
Tumor Microenvironment
Blood Cells
Therapeutics
Drug Therapy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Kawakami, Y., Kawase, Y., Ohizumi, A., Noji, S., Sakurai, T., & Fujita, T. (2012). [Biomarkers for cancer immunotherapy]. Nihon rinsho. Japanese journal of clinical medicine, 70(5), 759-766.

[Biomarkers for cancer immunotherapy]. / Kawakami, Yutaka; Kawase, Yoshie; Ohizumi, Azusa; Noji, Shinobu; Sakurai, Toshiharu; Fujita, Tomonobu.

In: Nihon rinsho. Japanese journal of clinical medicine, Vol. 70, No. 5, 05.2012, p. 759-766.

Research output: Contribution to journalArticle

Kawakami, Y, Kawase, Y, Ohizumi, A, Noji, S, Sakurai, T & Fujita, T 2012, '[Biomarkers for cancer immunotherapy].', Nihon rinsho. Japanese journal of clinical medicine, vol. 70, no. 5, pp. 759-766.
Kawakami Y, Kawase Y, Ohizumi A, Noji S, Sakurai T, Fujita T. [Biomarkers for cancer immunotherapy]. Nihon rinsho. Japanese journal of clinical medicine. 2012 May;70(5):759-766.
Kawakami, Yutaka ; Kawase, Yoshie ; Ohizumi, Azusa ; Noji, Shinobu ; Sakurai, Toshiharu ; Fujita, Tomonobu. / [Biomarkers for cancer immunotherapy]. In: Nihon rinsho. Japanese journal of clinical medicine. 2012 ; Vol. 70, No. 5. pp. 759-766.
@article{0544d664dab3403b81d869bfe2df0a21,
title = "[Biomarkers for cancer immunotherapy].",
abstract = "Immune-biomarkers and -assays are important for development of cancer immunotherapy to select the patients who are expected to respond to immunotherapy before or early after immunotherapy, to monitor immune induction following immunotherapy, and to evaluate anti-tumor effects early after immunotherapy. Comprehensive immune-evaluation including positive and negative immune responses against cancer cells and identification of blood biomarkers which reflect immune-conditions in tumor microenvironment are required although direct evaluation of tumor tissues can be possible for some patients. Importance of immune responses has recently been recognized even for standard cancer treatments including chemotherapy and molecular target therapy. Therefore, immunological biomarkers may be useful for any cancer treatment.",
author = "Yutaka Kawakami and Yoshie Kawase and Azusa Ohizumi and Shinobu Noji and Toshiharu Sakurai and Tomonobu Fujita",
year = "2012",
month = "5",
language = "English",
volume = "70",
pages = "759--766",
journal = "Nihon rinsho. Japanese journal of clinical medicine",
issn = "0047-1852",
publisher = "Nipponrinsho Co., Inc.",
number = "5",

}

TY - JOUR

T1 - [Biomarkers for cancer immunotherapy].

AU - Kawakami, Yutaka

AU - Kawase, Yoshie

AU - Ohizumi, Azusa

AU - Noji, Shinobu

AU - Sakurai, Toshiharu

AU - Fujita, Tomonobu

PY - 2012/5

Y1 - 2012/5

N2 - Immune-biomarkers and -assays are important for development of cancer immunotherapy to select the patients who are expected to respond to immunotherapy before or early after immunotherapy, to monitor immune induction following immunotherapy, and to evaluate anti-tumor effects early after immunotherapy. Comprehensive immune-evaluation including positive and negative immune responses against cancer cells and identification of blood biomarkers which reflect immune-conditions in tumor microenvironment are required although direct evaluation of tumor tissues can be possible for some patients. Importance of immune responses has recently been recognized even for standard cancer treatments including chemotherapy and molecular target therapy. Therefore, immunological biomarkers may be useful for any cancer treatment.

AB - Immune-biomarkers and -assays are important for development of cancer immunotherapy to select the patients who are expected to respond to immunotherapy before or early after immunotherapy, to monitor immune induction following immunotherapy, and to evaluate anti-tumor effects early after immunotherapy. Comprehensive immune-evaluation including positive and negative immune responses against cancer cells and identification of blood biomarkers which reflect immune-conditions in tumor microenvironment are required although direct evaluation of tumor tissues can be possible for some patients. Importance of immune responses has recently been recognized even for standard cancer treatments including chemotherapy and molecular target therapy. Therefore, immunological biomarkers may be useful for any cancer treatment.

UR - http://www.scopus.com/inward/record.url?scp=84864523426&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864523426&partnerID=8YFLogxK

M3 - Article

C2 - 22619998

AN - SCOPUS:84864523426

VL - 70

SP - 759

EP - 766

JO - Nihon rinsho. Japanese journal of clinical medicine

JF - Nihon rinsho. Japanese journal of clinical medicine

SN - 0047-1852

IS - 5

ER -